In recent years, vaccination strategies using antigen-presenting cells (APC) have been under investigation. Antigen delivery using genetic immunization through ex vivo transduction of dendritic cells (DC) is supposed to enhance the induction of antitumor responses in humans by activating a broad range of peptide-specific CD8 + T cells. In this study, we compared the potential of adenoviral (Ad)-transduced versus peptide-pulsed DC to induce melanoma-antigen (Ag)-specific T-cell responses in vitro. Whereas gp100-peptidepulsed DC induced long-lasting specific CD8 + T-cell responses against single peptides, Ad-transduced DC induced broad and strong, specific immunity against various peptides of the gp100-Ag. Surprisingly, several restimulations led to decreasing gp100-specific and in parallel to increasing antiadenoviral T-cell responses. Nevertheless, those anti-adenoviral T-cell responses provided an 'adjuvant' effect by inducing an early release of high amounts of IL-2/IFN-g, therewith enhancing CTL induction in the initiation phase. Based on these data, we suggest a prime/boost vaccination strategy in melanoma patients -combining the use of Ad-DC and peptide-pulsed DC -to obtain efficient and long-term antitumor T-cell responses.
Introduction
Dendritic cells (DC) are professional antigen-presenting cells (APC) capable of stimulating primary T-cellmediated immune responses. 1, 2 Immunization with antigen-bearing DC efficiently primes CD4 + and CD8 + T cells resulting in a protective immunity against tumors and infectious agents. [3] [4] [5] [6] [7] Several clinical trials have shown that antigen-loaded DC seem to be ideal vehicles for the immunotherapy of human tumor patients. [8] [9] [10] Thus, a number of laboratories are currently investigating different loading strategies for cultured DC. [3] [4] [5] [6] [11] [12] [13] [14] [15] [16] Direct transduction of immunostimulatory DC with tumor antigen cDNA has several advantages when compared to peptides and proteins, including sustained intracellular expression of entire protein antigens and concurrent processing of multiple peptides on both MHC class-I and class-II molecules. In addition, expression of entire tumor antigens (Ag) circumvents the need for prior knowledge of the patients' HLA type or the particular peptide-epitopes appropriate for the expressed HLA type.
In recent studies, recombinant replication-deficient E1-substituted adenoviral vectors have been employed for strong gene expression in cultured murine or human DC.
In mice, these adenovirus-transduced DC (Ad-DC) are capable of inducing tumor antigen-specific CTL in vivo associated with protection against tumor challenge. 6, 11, 12, 14, 16 We and others have recently demonstrated that peptide-pulsed mature DC are able to induce specific antitumor immune responses in vitro and in vivo. [7] [8] [9] [10] In our current study, we investigated whether the in vitro priming of T cells with antigen-transduced, mature DC resulted in a more efficient induction of T effector cells with broad reactivity when compared to peptide-pulsed mature DC. To induce Ag-specific immune responses in CD8 + T cells, the melanoma-specific Ag glycoprotein 100 (gp100) was used to transduce mature DC. Gp100 is a human melanocyte lineage-restricted, non-mutated Ag that is well characterized and expressed in primary cutaneous melanoma as well as in distant metastases. Several dominant (G154, G209, G280, G457 and G476) and subdominant (G177, G570) HLA-A201-restricted epitopes have been identified and may be useful Ag for specific immunotherapy. 17, 18 Analysis of the T-cell populations induced revealed that CD8 + T cells stimulated with Ad-DC showed an early and strong, Ag-specific upregulation of IFN-g and IL-2 after stimulation and specific reactivity against several gp100-epitopes. Surprisingly, gp100-specific T-cell responses induced with Ad-DC decreased upon in vitro restimulation, while in parallel, adenovirusspecific, MHC class-I restricted T-cells were elicited. In contrast, peptide-pulsed DC were able to induce longlasting, melanoma-Ag-specific T cells. Combination of both loading strategies resulted in a significant enhancement of IFN-g-producing, peptide-specific CD8 + T cells against various gp100-epitopes.
Results
Transduction of mature DC with recombinant adenovirus results in DC that do not differ in phenotype and cytokine production when compared to untreated DC Transduction of DC with recombinant adenovirus encoding gp100 was performed on day 6, 6 h after stimulation with a cocktail of cytokines, by the addition of purified virus to the DC culture at an MOI of 300. As shown before, the expression levels of surface molecules like CD80/86, CD83 and HLA-DR were similar to those of untransduced DC. 19 In general, more than 50% of DC were transduced at an MOI of 300 without significant cytotoxic effects and with transgene expression being detectable for at least 3 days after transduction of DC (data not shown). To investigate whether transduction led to an altered cytokine production in Ad-modified DC, supernatants of untreated and Ad-transduced DC were analyzed by ELISA. As shown in Figure 1 , both DC populations did not show any IFN-g production, whereas TNF-a levels were similar in Ad-transduced and untreated DC.
Peptide-pulsed and Ad-transduced DC induce a similar expansion of the total number of CD8 + T cells
For primary stimulation as well as restimulation of CD8 + T cells, DC were either pulsed with a dominant epitope of the gp100-Ag (50 mM) -described here as G154 -or transduced using Ad-gp100 at an MOI of 300. As transduction of DC using adenoviral vectors results in a transient suppression of their T-cell stimulatory capacity early after viral infection, DC were used at day 3 after transduction in our experiments. 19 1 Â 10 5 Agloaded DC were used for primary stimulation and restimulation of 1 Â 10 6 CD8 + T cells. MelanA/MART-1-peptide-pulsed DC served as a control. After every stimulation, the total number of viable T cells was determined by trypan blue exclusion. As shown in Figure 2 , T-cell stimulation with either peptide-pulsed or transduced DC resulted in an equal expansion of CD8 + T cells.
Stimulation with Ad-transduced DC results in an early and strong Ag-specific induction of IFN-g and IL-2 production in CD8 + T cells
Next, we analyzed the cytokine profiles of the T-cell populations induced by comparing the use of peptidepulsed versus Ad-transduced DC for stimulation. After primary stimulation, IFN-g was only detectable in supernatants of gp100-transduced DC and not after stimulation with peptide-pulsed DC. In addition, cytokine levels induced by peptide-stimulation were much lower when compared to cytokine levels induced by Ad-DC after first restimulation (Figure 3a) . These results were confirmed by intracellular FACS staining of activated T cells. As shown in Figure 3b , Ad-DC induced not only higher numbers of IFN-g/IL-2 producing T cells, but also CD8 + T cells that produced enhanced amounts of IFN-g when looking at the mean fluorescence intensity. The same results were obtained for TNF-a production, whereas IL-4 and IL-10 were not detectable in any of the T-cell populations (data not shown). These data demonstrate that Ad transduction compared to peptide loading of mature DC results in an enhanced T-cell stimulatory capacity resulting in a strong and early cytokine production by CD8 + T cells.
In vitro stimulation with gp100-transduced DC identifies the gp100-peptide-specific repertoire of CD8 + T
cells in individual melanoma patients
To analyze the repertoire of gp100-specific T cells of individual melanoma patients, CD8 + T cells were isolated and stimulated with gp100-transduced DC. After the first restimulation, CD8 + T cells were tested in an IFN-g enzyme-linked immunospot (ELISPOT) assay. To assess the epitope specificity of the effector cells from each + T cells. DC were transduced on day 6, using a recombinant adenovirus encoding for gp100 at an MOI of 300 or left untreated. At day 8, untreated DC where pulsed with different peptides of gp100 (50 mM). Peptide-pulsed and Ad-transduced DC were used for primary stimulation and restimulations of syngeneic CD8
+ T cells at a ratio of 1:10. At the time point of every restimulation, the expansion of viable CD8 + T cells was determined by trypan blue exclusion. Results of a representative experiment out of 10 are presented.
Ad-transduced DC versus peptide-pulsed DC
A Tuettenberg et al donor, T2 cells pulsed individually with a panel of gp100-peptides were used as target cells. The frequencies of peptide-specific IFN-g-producing T cells of each patient are demonstrated in Figure 4 . In general, there were significant inter-individual differences in the peptide-specific T-cell repertoire. Whereas patients A and B had a much higher frequency of peptide-reactive T cells in general, the absolute number of peptide-specific, IFNg-producing T cells in patients C and D was significantly lower. Patient A showed strong reactivity against the G280 and G209 peptide and a minor but detectable amount of T cells reacting with the G154 and G476 peptide. Patient B revealed remarkable frequencies of G280-and G154-specific T cells. In patient C, only G154-specific T cells were detectable, whereas patient D had a weak but broad range of peptide-specific T cells (G280, G154, G476). The data demonstrate that melanoma patients show varying peptide specificities in their T-cell repertoire. Thus, for the development of an efficient vaccination strategy, it seems to be necessary to analyze the peptide-specific T-cell repertoire of each patient and to determine the relevant peptides suitable for DC loading prior to vaccination.
Ad-transduced DC induce broad Ag-specific T-cell responses that decrease after several restimulations when compared to peptide-pulsed DC Next, we compared the immunogenicity of gp100-transduced and gp100-peptide-pulsed DC. CD8 + T cells from melanoma patients were isolated, primed and restimulated in vitro with autologous, mature DC transduced with Ad-gp100 or pulsed with a relevant gp100 peptide as determined before ( Figure 4 ). After every restimulation, peptide-specific IFN-g production of the T cells induced was analyzed in ELISPOT assays. As demonstrated in Figure 5 , DC transduced with Ad-gp100 induced a higher frequency of G154-peptide-specific T cells than peptide-pulsed DC, detectable after the first restimulation. However, the number of G154-peptidespecific IFN-g-producing T cells decreased upon further In vitro priming with gp100-transduced DC identifies the gp100-peptide specific repertoire of CD8 + T cells in individual melanoma patients. To detect the gp100 peptide specificity in melanoma patients, CD8
+ T cells were isolated from frozen PBMC of four melanoma patients (A-D). T cells were stimulated in vitro using gp100-transduced DC. After the first restimulation, peptide-specific IFN-g production was analyzed in ELISPOT assays. T2 cells pulsed with a variety of different gp100 peptides were used as target cells as indicated.
Ad-transduced DC versus peptide-pulsed DC A Tuettenberg et al restimulations with gp100-Ad-DC. In parallel, there was no detectable expansion of other peptide specificities of the T-cell population induced ( Figure 5 ), excluding a dilution effect of the G154-specific population with each round of stimulation. These data indicate that T cells lost their peptide specificity following several restimulations with gp100-transduced DC. In contrast, gp100-peptidepulsed DC led to increasing Ag-specific and long-lasting IFN-g production in CD8
+ T cells after several restimulations and thus are suitable for long-term vaccination protocols.
Ad-DC induce virus-specific, MHC class-I restricted responses in CD8
+ T cells ( Figure 6 )
As shown before, Ad-DC are able to induce the expansion of CD8 + T cells in vitro ( Figure 2 ) and to induce cytokine production in T cells ( Figure 3) . Next, we determined whether the decrease of gp100-peptidespecific CD8 + T cells was due to the induction of increasing anti-adenoviral T-cell responses. Therefore, CD8 + T cells induced by Ad-DC were analyzed in ELISPOT assays after the third restimulation. Several rounds of restimulation led to T cells that showed IFN-g production specific for Adgp100-transduced DC ( Figure  6a ). To analyze whether the T-cell responses were directed against the gp100-Ag itself or against viral antigens co-presented on the transduced DC, Ad-EGFPtransduced DC, containing the identical viral backbone but a distinct Ag insert (EGFP) were used as control targets. As demonstrated in Figure 6b , T cells showed high levels of IFN-g production specific for adenoviral particles co-presented on the surface of Ad-transduced DC. This specific cytokine production was MHC class-I restricted, as the addition of blocking antibodies was able to suppress the IFN-g production completely. Direct comparison of the G154-specific and the Ad-specific Tcell responses after the first and the third restimulation revealed that Ad-specific responses increased upon several restimulations, whereas the G154-specific responses in parallel showed a remarkable decrease (Figure 6b ).
Virus-specific T-cell responses provide an adjuvant effect in the induction of melanoma-Ag-specific T-cell immunity (Figure 7) The data suggested that peptide-pulsed DC in contrast to Ad-transduced DC are more suitable for the use in longterm vaccination protocols as they were able to induce long-lasting melanoma-Ag-specific T-cell responses. But the early and strong upregulation of cytokines even after primary stimulation (Figure 3 ) and the higher frequency of peptide-specific T cells after the first restimulation using Ad-DC ( Figure 5) suggested that viral Ag could + T cells were analyzed in ELISPOT assays after three restimulations using gp100-transduced DC. Unpulsed, gp100-transduced and EGFP-transduced DC served as target cells to detect the reactivity of CD8 + T cells against adenoviral particles. To analyze whether the virusspecific IFN-g production was MHC class-I restricted, blocking antibodies were added to the cocultures (10 mg/ml). Results of a representative experiment out of four are presented. (b) T cells were repetitively stimulated with Ad-DC. Ad-specific and G154-peptide-specific IFN-g production of the T-cell population induced was compared after the first and the third restimulation. Results of a representative experiment out of four are presented. Figure 5 Ad-transduced DC induce broad Ag-specific T cell responses that decrease after several restimulations. CD8 + T cells were repetitively stimulated either with DC pulsed with the G154-peptide or with Ad-gp100 transduced DC. After every restimulation, peptide-specific IFN-g production was analyzed in ELISPOT assays. To detect peptide specificity, T2 cells pulsed with a variety of different gp100 peptides were used as target cells as indicated. Results of a representative experiment out of four are presented.
Ad-transduced DC versus peptide-pulsed DC
A Tuettenberg et al provide an adjuvant effect by the early and strong induction of cytokines such as IFN-g and IL-2 in the initiation phase. To test this hypothesis, we combined both loading strategies. For the primary stimulation and the first restimulation of CD8 + T cells, we used Ad-DC encoding the gp100-Ag. Further restimulations of this Tcell population were performed using peptide-loaded DC. As a control, T cells were either stimulated up to three times with peptide-loaded DC or with Ad-DC as demonstrated before. All T-cell populations were tested after the third restimulation in an IFN-g ELISPOT assay.
As demonstrated in Figure 7 , the combination of the two loading procedures led to a high number of T cells specific for the G154 peptide of the gp100 antigen. Thus, priming of T cells with Ad-DC and boosting immune responses with a combination of relevant peptides might be ideal for clinical vaccination trials.
Discussion
In vitro transduction of mature human DC has been suggested to be an effective approach to genetic immunization as it results in DC strongly expressing the encoded antigen. 6, 11, 12, 14, 16, 20, 21 QUOTE "" These genetically modified DC are supposed to be superior to DC pulsed with limited numbers of defined peptides as they present the full array of possible CTL epitopes. Using DC as potent APC for vaccination trials in human cancer patients, it is necessary to define the best antigenloading strategy for successful immunotherapy. In the current study, we demonstrate that Ad-DC are able to elicit Ag-specific T-cell responses against various peptides of the gp100-Ag. T-cell responses occurred after priming and first restimulation, but decreased following further restimulations with Ad-DC. In parallel, adenoviral particles presented on the surface of Ad-DC induced dominant anti-adenoviral reactivity in CD8 + T cells from the same patients. In contrast, T cells primed and restimulated with peptide-pulsed DC induced longlasting, Ag-specific T-cell responses to single peptides in vitro. A combination of both loading strategies led even to a higher frequency of melanoma-antigen-specific CD8 + T cells after several restimulations. In our study, DC were susceptible to adenoviral transduction as they strongly expressed the encoded Ag and thus seemed to be ideal vectors for the optimal delivery of target Ag. In addition, Ad-DC displayed typical characteristics of mature DC including analysis of morphology, phenotype and allostimulatory function. In our hands, also cytokine profiles of Ad-DC and untreated DC were similar. As previously shown, the adenoviral transduction did not have any influence on the maturation state of the resulting DC population. 19, [22] [23] [24] In mice, the use of DC infected with tumor-associated Ag for immunization and the induction of T-cellmediated protective immunity resulting in the reduction of established tumors could be demonstrated. Immunization with Ad-DC induced long-lasting antitumor activity even after single administration when compared to the direct injection of Ad-gp100 alone. Nevertheless, these investigators did not analyze repetitive stimulations using Ad-DC and they did not compare their immunization strategy to peptide-pulsed DC. 12, 14, 25 In the human system, a direct comparison of mature, peptide-pulsed versus Ad-transduced DC in the induction of long-lasting, Ag-specific T-cell immunity also is missing. In agreement with our results, several groups demonstrated that virally transduced DC were able to prime Ag-specific CD8 + T cells in vitro. 23, 26 Nevertheless, there was no direct comparison to the use of peptideloaded DC. In addition, most investigators used immature, peptide-pulsed or infected DC for priming and restimulation of CD8 + T cells. 22, 23, [26] [27] [28] [29] Philip et al showed that immature DC loaded with MART-1 peptide or infected with an adenoviral construct were functionally equivalent in the induction of peptide-specific CTL in vitro. 27 We have recently shown that peptide-pulsed immature DC are inferior to mature DC in inducing peptide-specific T-cell responses in vitro. 7 This fact may explain our findings that mature, peptide-pulsed DC induce superior CTL responses following several restimulations when compared to Ad-DC. Furthermore, repetitive in vitro stimulations using immature DC induce regulatory T cells and should therefore be avoided in cancer vaccination strategies. 30, 31 The long-term influence of repetitive stimulations on the T-cell response using infected DC or the induction of antiviral cellular immune responses has not been analyzed so far. In our system, mature Ad-DC were able to induce CTL specific for several of the known gp100 peptides after the first restimulation. Compared to peptide-pulsed DC, the responses were transient and decreased following further restimulations, while, in parallel, anti-adenoviral T-cell responses were elicited. Immunization with adenovirus alone elicits strong neutralizing anti-adenoviral antibody responses in mice and is therefore limited in application. 32 Furthermore, pre-existing Ad immunity especially in humans can impair efficient in vivo transduction after systemic administration. 33 The adenoviral transduction of DC is a possibility to minimize anti-Ad antibody production Figure 7 Virus-specific T-cell responses provide an adjuvant effect in the induction of melanoma-Ag-specific T-cell immunity. T cells were either stimulated and restimulated with peptide-loaded DC (Tc+G154) or Ad-DC (Tc-ad) as demonstrated before. A third group was primed and restimulated once using Ad-DC. Further restimulations were performed using DC pulsed with peptides (Tc-Ad+G154). Peptide (G154)-specific IFN-g production was tested after the third restimulation. The number of G154-peptide-specific IFN-g-producing T cells is presented (number of G154-specific IFN-g-producing T cells ¼ (number of IFN-g-producing T cells in the presence of T2+G154) -(number of IFN-g-producing T cells in the presence of T2+control peptides)). For statistical analysis, Student's ttest was performed. Results of a representative experiment out of three are presented.
Ad-transduced DC versus peptide-pulsed DC A Tuettenberg et al and to overcome pre-existing anti-Ad humoral immunity. Nevertheless, in our study, the induction of strong antiviral cellular immune responses using Ad-DC for the induction of tumor-antigen-specific T cells was observed. Our findings are in agreement with a study, demonstrating that Ad-infected DC stimulate human virus-specific T-cell responses in vitro and mediate virus-specific lysis in an HLA-restricted manner. 34 The data suggest that DC process and present Ag derived from the viral inoculum itself without a requirement for viral gene expression. The fact that adenovirus used for transduction of DC generates immune responses against the vector itself is significant, especially in view of the increasing use of adenovirus for human gene therapy, as anti-Ad immune responses may dilute tumor-antigen-specific CTL responses in the course of the vaccination process.
On the other hand, the anti-adenoviral T-cell responses induced may have several advantages. We demonstrate that T cells primed and restimulated using Ad-DC showed higher numbers of peptide-specific T cells after the first restimulation when compared to T cells induced by peptide-loaded DC. A possible explanation for this phenomenon is that the early anti-adenoviral T-cell responses provide an adjuvant effect by inducing the production of high amounts of IL-2 and IFN-g and thus enhance CTL induction in the initiation phase. Furthermore, Ad-DC may be able to trigger and expand memory precursors with either high-or low-affinity receptors as well as previously unprimed peptide-specific T cells resulting in a higher number of Ag-specific cells. In addition, priming of CD8 + T cells using Ad-DC identifies the peptide specific-repertoire of CD8 + T cells in individual melanoma patients and thus can help to define the relevant peptides for vaccination strategies in these patients. Despite all these advantages, for the expansion of the induced T-cell populations and to prevent the induction of strong anti-adenoviral immune responses with a subsequent loss of melanoma-peptidespecific T cells, peptide-pulsed mature DC are more suitable for long-term vaccination protocols. A prime/ boost vaccination strategy with the initial induction of immune responses by Ad-DC and a boost with peptide-pulsed DC at later stages as demonstrated herein in vitro should be evaluated also in vivo. This strategy of combining different loading procedures may lead to an improvement of tumor vaccines in melanoma patients.
Materials and methods
Culture media and cytokines X-VIVO-15 supplemented with 1% autologous plasma was used for the generation of mature CD83 + DC. T-cell lines were cultured in X-VIVO-20 (all media from BioWhittaker, MD, USA) and expanded using X-VIVO-20 supplemented with 10 U/ml IL-2 (Chiron/Behring, Marburg, Germany).
Final concentrations of human recombinant cytokines used in this study were: GM-CSF (Leukomax/Sandoz, Basel, Switzerland) 800 U/ml, IL-4 and IL-6 1000 U/ml, IL-1b and TNF-a 10 ng/ml (all from Strathmann Biotech GmbH, Hannover, Germany), and PGE 2 (Minprostin, Pharmacia-Upjohn, Heppenheim, Germany) 1 mg/ml.
Antibodies
Staining of immunomagnetically sorted T cells was performed with FITC-or PE-conjugated CD8 mAb (Coulter/Immunotech) and FITC-and PE-conjugated mouse-IgG isotypes (Coulter/Immunotech).
Generation. of mature CD83
+ DC DC were generated from peripheral blood mononuclear cells (PBMC) obtained from leukapheresis products of HLA-A2 + melanoma patients as previously described. 10 Briefly, PBMC were incubated in six-well plates (Corning/Costar, Bodenheim, Germany,) at 10 7 cells/3 ml/ well in X-VIVO-15 containing 1% autologous plasma for 30-40 min (371C, 5% CO 2 ). Non-adherent cells were rinsed off and the remaining cells were further cultured in X-VIVO-15, 800 U/ml GM-CSF and 1000 U/ml IL4. Cells were fed every other day (7 1 ml) with X-VIVO-15, 1600 U/ml GM-CSF, and 1000 U/ml IL4. On day 6, nonadherent immature DC were rinsed off the plates and transferred to fresh six-well plates in X-VIVO-15, 800 U/ ml GM-CSF and 1000 U/ml IL4. A cytokine cocktail containing 10 ng/ml IL-1b, 10 ng/ml TNF-a, 1000 U/ml IL-6 and 1 mg/ml PGE 2 was added to the cultures for terminal maturation. Mature, non-adherent DC were harvested on day 8.
Peptide loading of mature DC
The peptides used were chosen from the identified HLA class-I restricted epitopes from gp100 as reported by others. 17, 18 The peptides (synthesized at the Institute of 
Recombinant adenoviruses and transduction of DC
Recombinant E1-substituted, E3-deleted adenoviral vectors encoding gp100 (Adgp100) or green fluorescent protein (AdEGFP) as a control for transduction efficiency were constructed through Cre-lox recombination, propagated on CRE8 or 293 cells and purified by cesium chloride gradient density centrifugation and subsequent dialysis according to standard protocols. 35 Adenoviruses were added to DC cultures on day 6 at an MOI of 300 (ie 3 Â 10 8 pfu/10 6 DC/well). To analyze gene transfer efficiency, gp100 expression of DC was determined by immunohistochemistry staining with anti-gp100 mAb HMB-45 as previously described. 36 Briefly, cells were fixed and blocked and incubated for 1 h with the HMB-45 mAb (DAKO-HMB45, M634, Hamburg, Germany). Ag expression was detected by a second step Ab (DAKO) followed by ABC staining (DAKO). Gp100-positive cells were counted by blinded observers.
Preparation and stimulation of T cells

CD8
+ T lymphocytes were sorted from PBMC using MACS beads as indicated by the manufacturer (Miltenyi, Ad-transduced DC versus peptide-pulsed DC A Tuettenberg et al Bergisch-Gladbach, Germany). 1 Â 10 6 CD8 + T lymphocytes were stimulated with 1 Â 10 5 syngeneic DC either pulsed with different peptides of the gp100 antigen, with MelanA/MART-1 peptide as a control or Adgp100-transduced DC. 4-5 days after primary stimulation, activated T cells were expanded using IL-2 (10 U/ml). T cells were fed every other day and restimulated 14 days after primary stimulation using either Ad-treated or peptide-pulsed DC as indicated. Restimulations were repeated every 8-10 days, at the time point of every restimulation, the expansion of viable CD8 + T cells was determined by trypan blue exclusion. Supernatants were collected 24-48 h after stimulation and activated T cells were analyzed to determine their induced phenotype and cytokine production.
Flow cytometric analysis
T cells were washed in cold PBS/human serum albumin (HSA 0.5%). and incubated for 20 min at 41C with the indicated PE-or FITC-conjugated mAb diluted to the optimal concentration for immunostaining. After washing with cold PBS/HSA, the cells were washed three times and analyzed by flow cytometry (FACScalibur, Cellquest software, Becton Dickinson, Mountain View, CA, USA), data being collected on 5000-10000 viable cells.
Intracellular FACS staining
For intracellular analysis of cytokine production, anti-IFN-g-FITC and anti-IL-2-PE and PE/FITC-conjugated isotypic mAb were used according to manufacturer's instructions (Pharmingen, Hamburg, Germany). Briefly, monensin was added 3-4 h after restimulation to the activated T cells. After overnight incubation, cells were collected, washed, fixed and permeabilized (all reagents from Pharmingen) and stained with 0.5 mg of the above mentionned cytokine-specific mAb.
Cytokine ELISA
Commercially available ELISA specific for the human cytokines IFN-g, IL-4, IL-2, IL-12p40/70, IL-10 and TNFa (Pharmingen) were used as indicated by the manufacturer. Detection limits: 15.6 pg/ml.
Detection of tumor peptide-specific T cell frequencies
To determine the frequency of peptide-specific CD8 + T cells, an ELISPOT assay was performed 5 days after every restimulation as previously described. 7 T cells were harvested and cultured in 96-well nitrocellulose culture plates (Multiscreen, Millipore) coated with mAb for IFNg (anti-IFN-g, Mabtech, Stockholm, Sweden). HLA-A2 + T2 cells (75 x 10 3 /well, T2.A2 provided by P Cresswell, Yale University, New Haven, USA) were loaded with peptides (50 mM). After incubation for 20 h, cytokine release of individual T cells was detected by a second step antibody (Mabtech) followed by AEC staining (Vectastain ABC Kit, Linaris, Wertheim-Bettingen, Germany). Spots were counted by blinded observers.
